Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns

In April 2026, Replimune Group received a complete response letter from the FDA for its BLA seeking approval of RP1 plus nivolumab for advanced melanoma, despite earlier breakthrough therapy ...
YouTube on MSN

Trying Korea’s coolest noodles: UK crew taste naengmyeon & bulgogi cutlets!

Join Guvna B, Barney Artist, Manik MC, Kofi Stone, DJ Chux, and Jay Prince as they dive into the world of Korean cuisine with ...